Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Phaeophyceae, commonly known as brown seaweeds (such as kelp, Laminaria, Fucus, and others), have been investigated for their potential antithrombotic (blood clot prevention) properties, primarily due to their content of sulfated polysaccharides, particularly fucoidan. Several in vitro and animal studies indicate that fucoidan exhibits anticoagulant and antithrombotic activities, often through mechanisms similar to heparin, such as enhancing the activity of antithrombin III and inhibiting the coagulation cascade. Some studies have also documented the inhibition of platelet aggregation by fucoidan extracts.

However, while laboratory and preclinical evidence is promising, robust human clinical trials are lacking. Most of the available data are from cell-based or animal models, and there is limited evidence regarding efficacy, optimal dosing, and safety in humans. As a result, while there is legitimate scientific interest and early-stage evidence supporting the use of Phaeophyceae-derived compounds in blood clot prevention, the overall evidence base is still emerging and cannot be considered strong or definitive at this time. It is not a mainstream therapy for clot prevention, and its use should be approached with caution, especially in individuals already taking anticoagulant medications due to the potential for additive effects.

More about Phaeophyceae (unspecified)
More about Blood Clots (prevention of)

Other ingredients used for Blood Clots (prevention of)

Other health conditions supported by Phaeophyceae (unspecified)

Products containing Phaeophyceae (unspecified)